Your browser doesn't support javascript.
loading
Evolution of synchronous female bilateral breast cancers and response to treatment.
Hamy, Anne-Sophie; Abécassis, Judith; Driouch, Keltouma; Darrigues, Lauren; Vandenbogaert, Mathias; Laurent, Cecile; Zaccarini, Francois; Sadacca, Benjamin; Delomenie, Myriam; Laas, Enora; Mariani, Odette; Lam, Thanh; Grandal, Beatriz; Laé, Marick; Bieche, Ivan; Vacher, Sophie; Pierga, Jean-Yves; Brain, Etienne; Vallot, Celine; Hotton, Judicael; Richer, Wilfrid; Rocha, Dario; Tariq, Zakia; Becette, Veronique; Meseure, Didier; Lesage, Laetitia; Vincent-Salomon, Anne; Filmann, Natalie; Furlanetto, Jenny; Loibl, Sibylle; Dumas, Elise; Waterfall, Joshua J; Reyal, Fabien.
Affiliation
  • Hamy AS; Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France.
  • Abécassis J; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France.
  • Driouch K; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France.
  • Darrigues L; INRIA, Université Paris-Saclay, CEA, Palaiseau, France.
  • Vandenbogaert M; Pharmacogenomics Unit, Department of Genetics, PSL University, Institut Curie, Paris, France.
  • Laurent C; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris, France.
  • Zaccarini F; Translational Research Department, Institut Curie Research Center, PSL University, Paris, France.
  • Sadacca B; INSERM U830, Institut Curie, PSL University, Paris, France.
  • Delomenie M; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France.
  • Laas E; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris, France.
  • Mariani O; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France.
  • Lam T; INSERM U830, Institut Curie, PSL University, Paris, France.
  • Grandal B; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris, France.
  • Laé M; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris, France.
  • Bieche I; Biological Resource Center, Department of Pathology, Department of Diagnostic and Theranostic Medicine, Institut Curie, PSL University, Paris, France.
  • Vacher S; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris, France.
  • Pierga JY; Department of Gynecology and Obstetrics, Geneva University Hospitals, Geneva, Switzerland.
  • Brain E; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France.
  • Vallot C; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris, France.
  • Hotton J; Biological Resource Center, Department of Pathology, Department of Diagnostic and Theranostic Medicine, Institut Curie, PSL University, Paris, France.
  • Richer W; Department of Pathology, Centre Henri Becquerel, INSERM U1245, UNIROUEN, University of Normandie, Rouen, France.
  • Rocha D; Pharmacogenomics Unit, Department of Genetics, PSL University, Institut Curie, Paris, France.
  • Tariq Z; INSERM U1016, Faculty of Pharmaceutical and Biological Sciences, Université de Paris Cité, Paris, France.
  • Becette V; Pharmacogenomics Unit, Department of Genetics, PSL University, Institut Curie, Paris, France.
  • Meseure D; Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France.
  • Lesage L; Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France.
  • Vincent-Salomon A; Translational Research Department, Institut Curie Research Center, PSL University, Paris, France.
  • Filmann N; CNRS UMR3244, Institut Curie, PSL University, Paris, France.
  • Furlanetto J; Department of Surgical Oncology, Institut Godinot, Reims, France.
  • Loibl S; Translational Research Department, Institut Curie Research Center, PSL University, Paris, France.
  • Dumas E; Translational Immunotherapy Team, INSERM U932, Institut Curie, PSL University, Paris, France.
  • Waterfall JJ; Translational Immunotherapy Team, INSERM U932, Institut Curie, PSL University, Paris, France.
  • Reyal F; Pharmacogenomics Unit, Department of Genetics, PSL University, Institut Curie, Paris, France.
Nat Med ; 29(3): 646-655, 2023 03.
Article in En | MEDLINE | ID: mdl-36879128
ABSTRACT
Synchronous bilateral breast cancer (sBBC) occurs after both breasts have been affected by the same germline genetics and environmental exposures. Little evidence exists regarding immune infiltration and response to treatment in sBBCs. Here we show that the impact of the subtype of breast cancer on levels of tumor infiltrating lymphocytes (TILs, n = 277) and on pathologic complete response (pCR) rates (n = 140) differed according to the concordant or discordant subtype of breast cancer of the contralateral tumor luminal breast tumors with a discordant contralateral tumor had higher TIL levels and higher pCR rates than those with a concordant contralateral tumor. Tumor sequencing revealed that left and right tumors (n = 20) were independent regarding somatic mutations, copy number alterations and clonal phylogeny, whereas primary tumor and residual disease were closely related both from the somatic mutation and from the transcriptomic point of view. Our study indicates that tumor-intrinsic characteristics may have a role in the association of tumor immunity and pCR and demonstrates that the characteristics of the contralateral tumor are also associated with immune infiltration and response to treatment.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2023 Document type: Article Affiliation country: Francia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2023 Document type: Article Affiliation country: Francia
...